272 related articles for article (PubMed ID: 31122991)
21. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
[TBL] [Abstract][Full Text] [Related]
22. In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Kan S; Song N; Pang Q; Mei H; Zheng H; Li D; Cui F; Lv G; An R; Li P; Xiong Z; Fan S; Zhang M; Chen Y; Qiao Q; Liang X; Cui M; Li D; Liao Q; Li X; Liu W
Mycopathologia; 2023 Apr; 188(1-2):99-109. PubMed ID: 36378354
[TBL] [Abstract][Full Text] [Related]
23. Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.
Sobel JD; Nyirjesy P
Future Microbiol; 2021 Dec; 16():1453-1461. PubMed ID: 34783586
[TBL] [Abstract][Full Text] [Related]
24. Species Distribution and Antifungal Susceptibility Profiles of Isolates from Women with Nonrecurrent and Recurrent Vulvovaginal Candidiasis.
Rolo J; Faria-Gonçalves P; Barata T; Oliveira AS; Gaspar C; Ferreira SS; Palmeira-de-Oliveira R; Martinez-de-Oliveira J; Costa-de-Oliveira S; Palmeira-de-Oliveira A
Microb Drug Resist; 2021 Aug; 27(8):1087-1095. PubMed ID: 33646045
[TBL] [Abstract][Full Text] [Related]
25. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Phillips NA; Rocktashel M; Merjanian L
Drug Des Devel Ther; 2023; 17():363-367. PubMed ID: 36785761
[TBL] [Abstract][Full Text] [Related]
26. Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Collins LM; Moore R; Sobel JD
J Low Genit Tract Dis; 2020 Jan; 24(1):48-52. PubMed ID: 31860575
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of a medical grade honey formulation (L-Mesitran) in comparison with fluconazole in the treatment of women with recurrent vulvovaginal candidiasis: protocol for a randomised controlled trial (HONEY STUDY).
van Riel SJJM; Lardenoije CMJG; Wassen MMLH; van Kuijk SMJ; Cremers NAJ
BMJ Open; 2023 Aug; 13(8):e070466. PubMed ID: 37640455
[TBL] [Abstract][Full Text] [Related]
28. "Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) - A systematic review and meta-analysis".
Siddiqui T; Kumar KA; Iqbal A; Doultani PR; Ashraf T; Eqbal F; Siddiqui SI
Heliyon; 2023 Nov; 9(11):e20495. PubMed ID: 37920530
[TBL] [Abstract][Full Text] [Related]
29. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Martens MG; Maximos B; Degenhardt T; Person K; Curelop S; Ghannoum M; Flynt A; Brand SR
Am J Obstet Gynecol; 2022 Dec; 227(6):880.e1-880.e11. PubMed ID: 35863457
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy.
Crouss T; Sobel JD; Smith K; Nyirjesy P
J Low Genit Tract Dis; 2018 Oct; 22(4):382-386. PubMed ID: 29975334
[TBL] [Abstract][Full Text] [Related]
31. Virulence is one of the mechanisms of vulvovaginal candidiasis recurrence, rather than drug resistance.
Li X; Chen S; Lyu X; Tian J
Med Mycol; 2022 Nov; 60(11):. PubMed ID: 36328948
[TBL] [Abstract][Full Text] [Related]
32. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.
Brand SR; Degenhardt TP; Person K; Sobel JD; Nyirjesy P; Schotzinger RJ; Tavakkol A
Am J Obstet Gynecol; 2018 Jun; 218(6):624.e1-624.e9. PubMed ID: 29534874
[TBL] [Abstract][Full Text] [Related]
33. Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern.
Khaksar Baniasadi A; Ayatollahi Mosavi SA; Sharifi I; Bamorovat M; Salari S; Ahmadi A; Amanizadeh A; Agha Kuchak Afshari S
J Obstet Gynaecol Res; 2022 Dec; 48(12):3292-3303. PubMed ID: 36184563
[TBL] [Abstract][Full Text] [Related]
34. Distinct host immune responses in recurrent vulvovaginal candidiasis and vulvovaginal candidiasis.
Ge G; Yang Z; Li D; Zhang N; Chen B; Shi D
Front Immunol; 2022; 13():959740. PubMed ID: 35967437
[TBL] [Abstract][Full Text] [Related]
35. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis.
Ferris DG; Nyirjesy P; Sobel JD; Soper D; Pavletic A; Litaker MS
Obstet Gynecol; 2002 Mar; 99(3):419-25. PubMed ID: 11864668
[TBL] [Abstract][Full Text] [Related]
36. Beyond fluconazole: A review of vulvovaginal candidiasis diagnosis and treatment.
Hellier SD; Wrynn AF
Nurse Pract; 2023 Sep; 48(9):33-39. PubMed ID: 37643144
[TBL] [Abstract][Full Text] [Related]
37. Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections.
Esfahani A; Omran AN; Salehi Z; Shams-Ghahfarokhi M; Ghane M; Eybpoosh S; Razzaghi-Abyaneh M
Microb Pathog; 2022 Sep; 170():105696. PubMed ID: 35921954
[TBL] [Abstract][Full Text] [Related]
38. Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
Barnes KN; Yancey AM; Forinash AB
Ann Pharmacother; 2023 Jan; 57(1):99-106. PubMed ID: 35502451
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan.
Mikamo H; Matsumizu M; Nakazuru Y; Okayama A; Nagashima M
J Infect Chemother; 2015 Jul; 21(7):520-6. PubMed ID: 25887336
[TBL] [Abstract][Full Text] [Related]
40. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
Sobel JD; Wiesenfeld HC; Martens M; Danna P; Hooton TM; Rompalo A; Sperling M; Livengood C; Horowitz B; Von Thron J; Edwards L; Panzer H; Chu TC
N Engl J Med; 2004 Aug; 351(9):876-83. PubMed ID: 15329425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
